Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer (STAR-BREAST)
Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY
It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast specialists and referred to a geneticist. The artificial intelligence-based tool to be used in this study is developed by the startup WeConecta, which will collect data via WhatsApp about the patients' family cancer history with the aim of predicting the genetic risk of developing breast cancer.
Eligibility
Participation Requirements
Sex: Female
Healthy Volunteers: f
View:
• female patients,
• aged 18 years or older,
• identified as high genetic risk by breast surgeons,
• referred to a geneticist, and
• who agree to participate in the study.
Locations
Other Locations
Brazil
Research Site
WITHDRAWN
Golania
Research Site
RECRUITING
Porto Alegre
Research Site
NOT_YET_RECRUITING
Porto Alegre
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2025-08-20
Estimated Completion Date: 2026-08-11
Participants
Target number of participants: 800
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca